<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>512-THALIDOMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="THALIDOMIDE" rxcui="10432">
<ATC code="L04AX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIDANOSINE" rxcui="3364">
<ATC code="J05AF02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of peripheral neuropathy due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>512-THALIDOMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="THALIDOMIDE" rxcui="10432">
<ATC code="L04AX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STAVUDINE" rxcui="59763">
<ATC code="J05AF04" />
<ATC code="J05AR07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of peripheral neuropathy due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>512-THALIDOMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="THALIDOMIDE" rxcui="10432">
<ATC code="L04AX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ZALCITABINE" rxcui="3363">
<ATC code="J05AF03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of peripheral neuropathy due to addition of undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.</COMMENT>
</INTERACTION>
</INTERACTIONS>
